drugset / Trial / NCT01097096
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AMILOMOTIDE | Protein / enzyme biologic | 150 ug | Intramuscular |
| Comparator | AMILOMOTIDE | Protein / enzyme biologic | 450 ug | Intramuscular |
| Comparator | Alum | Unknown | — | — |
| Comparator | MF59 | Other / unclassified | — | — |